Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 21, 2020

Australian researchers launch ASCOT study for Covid-19

Researchers at Royal Melbourne Hospital in Australia have launched the AustralaSian Covid-19 trial (ASCOT) to study two existing drugs for treating coronavirus.

Researchers at Royal Melbourne Hospital in Australia have launched the AustralaSian Covid-19 trial (ASCOT) to study two existing drugs for treating coronavirus.

The trial is designed to assess the safety and effectiveness of lopinavir/ritonavir and hydroxychloroquine at more than 70 hospitals across the country.

In addition, the ASCOT study will involve 11 hospitals in New Zealand.

In laboratory tests, HIV medication lopinavir/ritonavir, and malaria drug hydroxychloroquine demonstrated the ability to stop SARS-CoV-2, the novel coronavirus that causes Covid-19.

The ASCOT study will evaluate the ability of these drugs to prevent disease progression to the point when patients would require a ventilator in the intensive care unit (ICU).

Royal Melbourne Hospital infectious diseases clinician Steven Tong said: “We have designed the trial so that it’s responsive and adaptive. This means that if one of the drugs is proving to be effective, we can adapt the trial to focus on that treatment. Conversely, if a drug isn’t effective, or is causing severe side effects, we can stop it.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

“Having such a coordinated approach nationally and in New Zealand means that not only can many patients participate, but we can also generate the evidence as quickly as possible. Ideally, as other potential treatments become available, these can also be tested within the coordinated framework of ASCOT.”

The trial will randomise patients to receive various treatments and some participants may not receive lopinavir/ritonavir or hydroxychloroquine.

This design is intended to compare the impact of different drugs on Covid-19 patients.

Tong added: “This will allow us to answer whether patients who received a specific drug fare better, worse or the same compared to patients who received a different drug or standard of care.

Additional sites for the ASCOT study are expected to be initiated this week.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU